At Adelaide Eye and Retina Centre, we are actively involved in clinical research to help better patient outcomes and offer opportunities for patients to access novel therapeutics. Some of these therapies may be novel doses of currently available medications, new medications such as gene therapy and new medication delivery systems such as drops instead of injections.
If patients/participants are enrolled in studies their care is undertaken without cost and transport is often provided to and from visits. However the studies have very strict inclusion and exclusion criteria and so some patients/participants will not be eligible.
Some studies are observational, and others are interventional. We are currently recruiting for a number of studies which involve patients with intermediate AMD, nascent geographic atrophy, geographic atrophy, neovascular age-related macular degeneration, all forms of retinal vein occlusion (BRVO, CRVO and HRVO) and centre-involving diabetes-related macular oedema.
CURRENTLY RECRUITING TRIALS:
SIENNA
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- ≥50 and ≤85 years of age at time of signing ICF
- Total GA area in the study eye measuring between ≥2.5mm² and ≤17.5mm² and must meet following criteria:
- Presence of perilesional hyperautofluorescence in the banded or diffuse pattern
- GA lesion is within 1500µm of foveal centre point
- GA lesion can be completely visualized on the macula centered FAF image
- GA lesion can be measured separately from areas of peripapillary atrophy
- BCVA of 55 letters or better (6/24) in the study eye
- Willing and able to comply with clinic visits including completion of full series of meningococcal vaccinations and pneumococcal vaccination
- History or current evidence of MNV and/or exudation or PPCNV in EITHER eye
- Prior or current IVT treatment of any kind for any indication in EITHER eye, except approved or investigational IVT complement inhibitor therapy or anti-VEGF therapy as long as last dose was ≥ 6 months prior to randomization
- History of solid organ or bone marrow transplantation
- Malignancy within the past 3 years (except adequately treated bcc or scc skin cancer or in situ cervical/anal cancer)
SANOFI – DFI18231
A Phase 1/2, Study to Evaluate the Safety, Tolerability, and Efficacy of One-time Intravitreal Dose of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
- ≥60 years of age at time of signing ICF
- GA lesion area must meet one of the 2 criteria:
- Non-foveal GA lesion area measuring ≥2.5 to ≤14.0 mm²
- Foveal GA lesion area measuring ≥2.5 to ≤14.0 mm² in the study eye, AND patient has LLVD (defined as the difference between BCVA and LLVA) of >20 letters in the study eye
- If GA lesion is multifocal, at least 1 single lesion measuring >1.25mm² (0.5 disc area)
- GA completely visualized on the macula centered image and photographed in its entirety
- GA able to be measured separately from any areas of peripapillary atrophy
- Study eye must have hyper autofluorescence (of any pattern) in the junctional zone of GA
- BCVA of ≥34 ETDRS letters (6/60 or better)
- Current evidence of neovascularization or history of anti-VEGF treatment in the study eye. Presence of nAMD in the fellow eye is permitted and capped at 25% of the total population
- Presence of any pathology that may affect assessment of VA (ERM, macular edema, subretinal fibrosis, RPE tears, CSR etc)
- Intraocular surgery in the study eye within the past 3 months of enrolment or a likely candidate for intraocular surgery within 1 year of study intervention
- History of vitrectomy or corneal transplant in the study eye
- Uncontrolled glaucoma in the study eye defined as IOP >21mmHg accompanied by EITHER a CDR of ≥0.8 OR current use of >2 IOP lowering medications
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
This is a prospective, cross-sectional, multi-center, observational study to collect and develop a meticulously curated and diverse AMD benchmark dataset, featuring reference standard level 1 classification and comprehensive annotation of images.
-
Inclusion Criteria:
- Participants greater than or equal to 50 years of age at time of signing Informed Consent Form
- Willing to comply with all study procedures and sign the Informed Consent Form (ICF)
- Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center.
- Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed.
- Unable to acquire adequate quality images, as evaluated by the Central Reading Center
- Severe vision loss requiring urgent surgery
- Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light
- A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study
- Unwilling to sign informed consent form
- Currently or previously enrolled in an interventional AMD clinical trial
Fax
For urgent referrals:
(08) 8212 3302
Please email us for less urgent contact:
admin@adelaideeye.com.au
Adelaide Eye and Retina Centre
18 North Terrace, Adelaide.
We are located on the second floor.
18 North Terrace, Adelaide
Marion Eye and Retina Centre
530 Marion Road, Plympton Park.